128. A pharmaceutical composition comprising

a therapeutically effective human dose of an immunogenic first peptide derived from a cancer associated antigen

wherein said peptide comprises an epitope of 8-11 amino acids, wherein said epitope has the amino acid V, A or T at position 2 and the amino acid L, I, V, M or A at its carboxy terminus;

said peptide coupled to a second peptide which second peptide is not derived from said cancer associated antigen and wherein said additional peptide is a Pan DR binding peptide.

129. The composition of claim 128 wherein said first peptide contains less than about 15 amino acid residues.

130. The composition of claim 128 wherein said peptide has V at position 2 and L at the C-terminus.

131. The compound of claim 128 wherein said first peptide has V at position 2 and I at the C-terminus.

132. The compound of claim 128 wherein said first peptide has V at position 2 and V at the C-terminus.

133. The compound of claim 128 wherein said first peptide has V at position 2 and M at the C-terminus.

134. The compound of claim 128 wherein said first peptide has V at position 2 and A at the C-terminus.

135. The compound of claim 128 wherein said first peptide has A at position 2 and L at the C-terminus.

136. The compound of claim 128 wherein said first peptide has A at position 2 and I at the C-terminus.

137. The compound of claim 128 wherein said first peptide has A at position 2 and V at the C-terminus.

138. The compound of claim 128 wherein said first peptide has A at position 2 and M at the C-terminus.

139. The compound of claim 128 wherein said first peptide has A at position 2 and A at the C-terminus.

140. The compound of claim 128 wherein said first peptide has T at position 2 and L at the C-terminus.

141. The compound of claim 128 wherein said first peptide has T at position 2 and I at the C-terminus.

142. The compound of claim 128 wherein said first peptide has T at position 2 and V at the C-terminus.

143. The compound of claim 128 wherein said first peptide has T at position 2 and M at the C-terminus.

144. The compound of claim 128 wherein said first peptide has T at position 2 and A at the C-terminus.

145. The peptide of claim 137 which is KMADLVGFLV.